258 related articles for article (PubMed ID: 32981422)
1. AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery.
Baker JD; Uhrich RL; Strovas TJ; Saxton AD; Kraemer BC
SLAS Discov; 2021 Mar; 26(3):400-409. PubMed ID: 32981422
[TBL] [Abstract][Full Text] [Related]
2. MSUT2 is a determinant of susceptibility to tau neurotoxicity.
Guthrie CR; Greenup L; Leverenz JB; Kraemer BC
Hum Mol Genet; 2011 May; 20(10):1989-99. PubMed ID: 21355046
[TBL] [Abstract][Full Text] [Related]
3. Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.
Wheeler JM; McMillan P; Strovas TJ; Liachko NF; Amlie-Wolf A; Kow RL; Klein RL; Szot P; Robinson L; Guthrie C; Saxton A; Kanaan NM; Raskind M; Peskind E; Trojanowski JQ; Lee VMY; Wang LS; Keene CD; Bird T; Schellenberg GD; Kraemer B
Sci Transl Med; 2019 Dec; 11(523):. PubMed ID: 31852801
[TBL] [Abstract][Full Text] [Related]
4. Targeting Pathological Tau by Small Molecule Inhibition of the Poly(A):MSUT2 RNA-Protein Interaction.
Baker JD; Uhrich RL; Strovas TJ; Saxton AD; Kraemer BC
ACS Chem Neurosci; 2020 Aug; 11(15):2277-2285. PubMed ID: 32589834
[TBL] [Abstract][Full Text] [Related]
5. Distinct Poly(A) nucleases have differential impact on sut-2 dependent tauopathy phenotypes.
Kow RL; Strovas TJ; McMillan PJ; Jacobi AM; Behlke MA; Saxton AD; Latimer CS; Keene CD; Kraemer BC
Neurobiol Dis; 2021 Jan; 147():105148. PubMed ID: 33184027
[TBL] [Abstract][Full Text] [Related]
6. Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.
McMillan PJ; Benbow SJ; Uhrich R; Saxton A; Baum M; Strovas T; Wheeler JM; Baker J; Liachko NF; Keene CD; Latimer CS; Kraemer BC
Brain; 2023 Aug; 146(8):3206-3220. PubMed ID: 36732296
[TBL] [Abstract][Full Text] [Related]
7. Potential neuroprotective strategies against tauopathy.
Wheeler JM; Guthrie CR; Kraemer BC
Biochem Soc Trans; 2012 Aug; 40(4):656-60. PubMed ID: 22817711
[TBL] [Abstract][Full Text] [Related]
8. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ
Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
[TBL] [Abstract][Full Text] [Related]
10. SPOP loss of function protects against tauopathy.
Eck RJ; Kow RL; Black AH; Liachko NF; Kraemer BC
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2207250120. PubMed ID: 36574656
[TBL] [Abstract][Full Text] [Related]
11. The neuropathological spectrum of neurodegenerative tauopathies.
Tolnay M; Probst A
IUBMB Life; 2003 Jun; 55(6):299-305. PubMed ID: 12938731
[TBL] [Abstract][Full Text] [Related]
12. Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.
Langerscheidt F; Wied T; Al Kabbani MA; van Eimeren T; Wunderlich G; Zempel H
J Neurol; 2024 Jun; 271(6):2992-3018. PubMed ID: 38554150
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
[TBL] [Abstract][Full Text] [Related]
14. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
15. Bin1 directly remodels actin dynamics through its BAR domain.
Dräger NM; Nachman E; Winterhoff M; Brühmann S; Shah P; Katsinelos T; Boulant S; Teleman AA; Faix J; Jahn TR
EMBO Rep; 2017 Nov; 18(11):2051-2066. PubMed ID: 28893863
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic landscape of tauopathies: challenges and prospects.
Cummings JL; Gonzalez MI; Pritchard MC; May PC; Toledo-Sherman LM; Harris GA
Alzheimers Res Ther; 2023 Oct; 15(1):168. PubMed ID: 37803386
[TBL] [Abstract][Full Text] [Related]
17. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
18. MSUT2 regulates tau spreading via adenosinergic signaling mediated ASAP1 pathway in neurons.
Xu H; Qiu Q; Hu P; Hoxha K; Jang E; O'Reilly M; Kim C; He Z; Marotta N; Changolkar L; Zhang B; Wu H; Schellenberg GD; Kraemer B; Luk KC; Lee EB; Trojanowski JQ; Brunden KR; Lee VM
Acta Neuropathol; 2024 Mar; 147(1):55. PubMed ID: 38472475
[TBL] [Abstract][Full Text] [Related]
19. Targeting tau: Clinical trials and novel therapeutic approaches.
VandeVrede L; Boxer AL; Polydoro M
Neurosci Lett; 2020 Jul; 731():134919. PubMed ID: 32380145
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
